Genentech’s Evrysdi Continues to Improve Motor Function and Survival in Babies With Type 1 Spinal Muscular Atrophy (SMA)
– More than twice as many babies (61% vs. 29%) were able to sit without support for at least five seconds after 24 months compared to 12 months of treatment – – Evrysdi increased survival and reduced need for permanent ventilation – – Evrysdi has proven efficacy across adults, children and babies 2 months and … [Read more…]